Based on these, MAGL inhibitors can be developed as possible therapeutic agents in the treatment of various diseases such as neurodegenerative disease, inflammation, pain, as well as cancer (Nomura et al., 2010; Taschler et al., 2011; Chen et al., 2012). This evidence concerns the gene MGLL and cancer.